415 Capital Doubles Down on MedTech with €150 Million Second Fund 

415 Capital Management GmbH (“415 Capital”), a global leader in medical technology venture capital, has announced the launch of its second fund, 415 Capital Fund II, with a target of €150 million ($165 million). This latest fund underscores the firm’s commitment to driving innovation in life-saving medical technologies, with a particular focus on cardiovascular and neurovascular diseases, two of the most pressing global health challenges and leading drivers of healthcare costs. 

A significant portion of the fund’s target commitments has already been secured from leading institutional investors. The European Investment Fund (EIF), KfW Capital, and Wachstumsfonds Deutschland, alongside over 20 institutional investors, including insurance companies, foundations, and asset managers, are among the key backers. Additionally, several high-profile family offices from Europe and North America, as well as prominent physician-innovators, have joined as investors. The final closing of 415 Capital Fund II is anticipated by the end of the first quarter of 2025. 

Building on a Strong Investment Track Record 

Since launching its first institutional fund in 2020, 415 Capital has been a trusted partner to MedTech entrepreneurs, investing in companies that have achieved major clinical, regulatory, and commercial milestones. The firm has already deployed capital from the new fund into two clinical-stage cardiovascular companies, with additional transactions expected in the coming months. 

Through its investments, 415 Capital has demonstrated a strong ability to generate value for investors while significantly improving patient outcomes worldwide. Over the past five years, its portfolio companies have attracted more than €600 million ($650 million) in follow-on financing from top-tier life science venture capital firms and corporate strategic investors. Notable investments include Supira Medical, R3 Vascular, CorFlow, Distalmotion, and TRiCares. 

In parallel with its fundraising success, 415 Capital has strengthened its investment leadership with the appointments of Azin Parhizgar, PhD, and Ruben Osnabrugge, MD, PhD, to its Investment Committee. Parhizgar, who has played a key role in shaping the firm’s platform since its inception, brings a unique combination of scientific, entrepreneurial, and operational expertise. Osnabrugge, who joined the firm in 2023, leverages his background in cardiac surgery, clinical trials, and healthcare economics to drive value across the portfolio. 

A Vision for the Future of MedTech 

Headquartered in Munich, Germany, 415 Capital specializes in MedTech investments across Europe, the U.S., and Israel. With nearly $200 million in assets under management, the firm remains focused on backing clinical-stage innovations in cardiovascular and neurovascular diseases. Additionally, 415 Capital selectively invests in neuromodulation, medical robotics, and technologies at the intersection of patient monitoring, medical imaging, and artificial intelligence. 

By leveraging a global network of Key Opinion Leaders and collaborations with renowned hospitals and clinical research institutions, 415 Capital provides its portfolio companies with deep strategic support. The firm has backed more than 50 MedTech startups to date, whose technologies are now helping physicians treat hundreds of thousands of patients annually. 

As 415 Capital continues to expand its impact in the MedTech sector, innovation remains at the core of its investment strategy—positioning the firm as a key player in advancing life-saving healthcare solutions. 

Join the Global MedTech Conversation at MedTech Malta 2025 

For those looking to connect with key players making a difference in medical technology, MedTech Malta 2025 is the place to be. Taking place on November 12-14, 2025, this premier event will bring together investors, entrepreneurs, and industry leaders for insightful discussions, networking, and collaboration. Secure your place today—book your tickets now!